A Phase 1 Study of IPI-145 in Patients with Advanced Hematologic Malignancies
For Dose Escalation/MTD Confirmation Only: Diagnosis of any advanced hematologic malignancy other than acute leukemia, CML in blast crisis and high risk or intermediate type 2 myelodysplastic syndrome. | For Expansion Cohort 1 Only: Diagnosis of indolent non- Hodgkin lymphoma (iNHL), mantle cell lymphoma (MCL) or chronic lymphocytic leukemia (CLL). | For Expansion Cohort 2 Only: Diagnosis of mature cutaneous or non-cutaneous T cell lymphomas (excluding lymphoblastic lymphoma). | For Expansion Cohort 3 Only: Diagnosis of diffuse large B-cell lymphoma (DLBCL) or transformed follicular NHL. | For Expansion Cohort 4 Only: Diagnosis of myeloproliferative neoplasms (myelofibrosis and all phases of CML), AML, MDS (including intermediate and high risk). | For Expansion Cohort 5 Only: Diagnosis of acute lymphocytic leukemia/lymphoblastic lymphoma (T-cell or B-cell).
What is the purpose of this trial?
The purpose of this study is to determine the safety, maximum tolerated dose and pharmacokinetics of IPI-145 in patients with advanced hematologic malignancies.
- 18 Years and older
Click here for detailed information about who can participate in this trial.
- Infinity Pharmaceuticals, Inc.
- November 2012
- Last Updated:
- Study HIC#:
Clinicaltrials.gov ID: Yale9889904